DeepMed Research

Galectin Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 14

Market Cap: $163.1M

Website

Clinical Trials

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Phase 2

Active, not recruiting

Conditions: Prevention of Esophageal Varices
Cirrhosis
NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: belapectin
Drug: Placebo

First Posted Date: 2020-04-28

Last Posted Date: 2025-04-11

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 357

Registration Number: NCT04365868

Locations: 🇺🇸
Impact Research Institute, Waco, Texas, United States
🇨🇱
Hospital de La Serena, La Serena, CHL, Chile
🇨🇱
Clínica Universidad de los Andes, Santiago, CHL, Chile

and more 151 locations

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: belapectin

First Posted Date: 2020-04-02

Last Posted Date: 2022-03-28

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 38

Registration Number: NCT04332432

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Phase 2

Completed

Conditions: Hypertension, Portal

Interventions: Drug: GR-MD-02
Drug: Placebo

First Posted Date: 2015-06-04

Last Posted Date: 2020-10-08

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 162

Registration Number: NCT02462967

Locations: 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
Florida Digestive Health Specialist, Lakewood Ranch, Florida, United States

and more 43 locations

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: GR-MD-02
Drug: Placebo

First Posted Date: 2015-04-20

Last Posted Date: 2020-10-08

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 30

Registration Number: NCT02421094

Locations: 🇺🇸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: GR-MD-02

First Posted Date: 2015-04-02

Last Posted Date: 2020-09-07

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 5

Registration Number: NCT02407041

Locations: 🇺🇸
Brooke Army Medical Ctr., San Antonio, Texas, United States

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Phase 1

Completed

Conditions: Non-Alcoholic Steatohepatitis (NASH)

Interventions: Drug: GR-MD-02
Drug: Placebo

First Posted Date: 2013-07-16

Last Posted Date: 2015-02-23

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 31

Registration Number: NCT01899859

Locations: 🇺🇸
Brooke Army Medical Ctr., San Antonio, Texas, United States

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer

Interventions: Drug: GM-CT-01
Drug: 5-Fluorouracil, Leukovorin, bevacizumab

First Posted Date: 2006-10-17

Last Posted Date: 2018-02-14

Lead Sponsor: Galectin Therapeutics Inc.

Registration Number: NCT00388700

Locations: 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Kaplan MC, Rechovot, Israel
🇮🇱
Sheba MC, Tel Hashomer, Israel

and more 1 locations

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Phase 2

Withdrawn

Conditions: Cancer of the Bile Duct
Gallbladder Cancer

Interventions: Drug: GM-CT-01
Drug: 5-Fluorouracil

First Posted Date: 2006-10-11

Last Posted Date: 2017-08-01

Lead Sponsor: Galectin Therapeutics Inc.

Registration Number: NCT00386516

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Barrett Cancer Center, Cincinnati, Ohio, United States
🇺🇸
University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

First Posted Date: 2005-05-13

Last Posted Date: 2012-03-06

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 20

Registration Number: NCT00110721

Locations: 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇮🇱
Soroka University Medical Center, Beer-Sheva, Israel
🇺🇸
Medical Oncology and Hematology, Waterbury, Connecticut, United States

and more 3 locations

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Phase 1

Completed

Conditions: Colorectal Cancer
Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer

First Posted Date: 2003-02-17

Last Posted Date: 2012-03-12

Lead Sponsor: Galectin Therapeutics Inc.

Target Recruit Count: 40

Registration Number: NCT00054977

Locations: 🇺🇸
Florida Oncology Associates, Jacksonville, Florida, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ochsner Cancer Institute, New Orleans, Louisiana, United States

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy